Free Trial

Phibro Animal Health (NASDAQ:PAHC) Stock Dropped to "Hold" by Zacks Research

Phibro Animal Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was downgraded by investment analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a report issued on Tuesday, Zacks reports.

Separately, Weiss Ratings raised Phibro Animal Health from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Phibro Animal Health currently has a consensus rating of "Hold" and a consensus target price of $46.50.

Read Our Latest Analysis on PAHC

Phibro Animal Health Stock Performance

Phibro Animal Health stock opened at $35.15 on Tuesday. The firm has a fifty day simple moving average of $36.89 and a two-hundred day simple moving average of $40.93. The company has a quick ratio of 1.28, a current ratio of 3.20 and a debt-to-equity ratio of 1.70. Phibro Animal Health has a twelve month low of $28.25 and a twelve month high of $60.08. The company has a market capitalization of $1.43 billion, a PE ratio of 10.59 and a beta of 0.42.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.78 by $0.01. The firm had revenue of $386.77 million for the quarter, compared to the consensus estimate of $382.42 million. Phibro Animal Health had a return on equity of 35.88% and a net margin of 6.66%. Research analysts expect that Phibro Animal Health will post 3.48 EPS for the current year.

Institutional Investors Weigh In On Phibro Animal Health

A number of large investors have recently made changes to their positions in the business. KBC Group NV purchased a new stake in shares of Phibro Animal Health in the 1st quarter worth about $29,000. Sterling Capital Management LLC increased its position in shares of Phibro Animal Health by 864.9% during the third quarter. Sterling Capital Management LLC now owns 714 shares of the company's stock valued at $26,000 after buying an additional 640 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Phibro Animal Health during the third quarter valued at about $39,000. Hughes Financial Services LLC raised its stake in Phibro Animal Health by 93.4% in the third quarter. Hughes Financial Services LLC now owns 1,659 shares of the company's stock worth $64,000 after buying an additional 801 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Phibro Animal Health by 14.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,851 shares of the company's stock worth $137,000 after buying an additional 498 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation develops and markets products for animal health and nutrition. Its portfolio includes vaccines, medicated feed additives, and nutritional specialty products designed to support the health and productivity of livestock and other animals. The company also supplies trace minerals and related products used in animal nutrition and other applications. Its products serve markets including poultry, cattle, swine, and aquaculture, and are sold to customers in the United States and internationally.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Phibro Animal Health Right Now?

Before you consider Phibro Animal Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.

While Phibro Animal Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines